iCAD (NASDAQ:ICAD) Stock Price Crosses Above 200 Day Moving Average – Should You Sell?

iCAD, Inc. (NASDAQ:ICAD)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.56 and traded as high as $2.13. iCAD shares last traded at $1.95, with a volume of 253,276 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded iCAD from a “sell” rating to a “hold” rating in a research note on Thursday, November 21st.

iCAD Stock Down 1.0 %

The firm has a market cap of $51.75 million, a P/E ratio of -15.00 and a beta of 1.43. The stock’s 50-day moving average is $1.78 and its 200-day moving average is $1.56.

Institutional Investors Weigh In On iCAD

An institutional investor recently raised its position in iCAD stock. Perritt Capital Management Inc increased its position in shares of iCAD, Inc. (NASDAQ:ICAD) by 14.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 159,900 shares of the technology company’s stock after purchasing an additional 19,917 shares during the quarter. Perritt Capital Management Inc owned approximately 0.60% of iCAD worth $208,000 at the end of the most recent quarter. 24.61% of the stock is owned by hedge funds and other institutional investors.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.